The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D, Brunner C, Walder D, Ziegler A, Abbasi R, Ladenstein RL, Noguera R, Martinsson T, Amann G, Schilling FH, Ussowicz M, Benesch M, Ambros PF, Ambros IM.
Bogen D, et al. Among authors: ambros pf, ambros im.
Int J Cancer. 2016 Jul 1;139(1):153-63. doi: 10.1002/ijc.30050. Epub 2016 Mar 22.
Int J Cancer. 2016.
PMID: 26910568
Free PMC article.